Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552769 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04552769: Completed Phase 2 study, sponsored by Stanford University.
NCT04552769 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552769, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2025-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552769
The ClinicalTrials.gov registry entry for NCT04552769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04552769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04552769 about?
NCT04552769 is a clinical study titled "Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer". The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
What is the current status of trial NCT04552769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-10. Estimated completion is 2025-01-05.
What interventions are being tested in trial NCT04552769?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04552769?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.